Plasmodium falciparum Kelch-13 artemisinin partial resistance markers in Fort Portal, Western Uganda, 2024
- PMID: 40265952
- PMCID: PMC12135530
- DOI: 10.1128/aac.01755-24
Plasmodium falciparum Kelch-13 artemisinin partial resistance markers in Fort Portal, Western Uganda, 2024
Abstract
In Fort Portal, Uganda, artemisinin resistance-associated mutations in Plasmodium falciparum Kelch13 (n = 126) were present in 4.8% (675V, 561H, and 441L). A mutation of unknown relevance, 490T, occurred in 9.5%. PfMDR1 variants suggested increased lumefantrine tolerance (N86, 100%). Mutation 500N was absent, and 199S occurred in 12.8%. The latter is of unknown relevance. These data indicate an incipient emergence of artemisinin resistance in a crucial location between Rwandan and Ugandan resistance hotspots and hardly affected DR Congo.
Keywords: PfK13; PfMDR1; Uganda; artemisinin resistance; molecular markers of resistance.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- World Health O. 2023. World malaria report 2023. World Health Organization, Geneva.
-
- Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, Namuganga JF, Katairo T, Legac J, Crudale RM, Tumwebaze PK, Nsobya SL, Cooper RA, Kamya MR, Dorsey G, Bailey JA, Rosenthal PJ. 2023. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med 389:722–732. doi:10.1056/NEJMoa2211803 - DOI - PMC - PubMed
-
- Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, Nair S, White MM, Dziekan J, Ling C, Proux S, Konghahong K, Jeeyapant A, Woodrow CJ, Imwong M, McGready R, Lwin KM, Day NPJ, White NJ, Nosten F. 2016. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar Border (2003-2013): the role of parasite genetic factors. Clin Infect Dis 63:784–791. doi:10.1093/cid/ciw388 - DOI - PMC - PubMed
-
- van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, Ul Islam A, Anvikar AR, Satpathi P, Satpathi S, Behera PK, et al. . 2020. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet 395:1345–1360. doi:10.1016/S0140-6736(20)30552-3 - DOI - PMC - PubMed
-
- Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, Legac J, Garg S, Giesbrecht D, Smith SR, Ceja FG, Nsobya SL, Bailey JA, Cooper RA, Rosenthal PJ. 2022. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun 13:6353. doi:10.1038/s41467-022-33873-x - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
